Penn Medicine and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their collaboration to advance cancer immunotherapy research at Penn Medicine’s Abramson Cancer Center (ACC). The renewal comes as PICI recently announced a $125 million investment across the PICI Network to expand research efforts and accelerate the development of innovative cancer immunotherapies. Penn was one of the founding institutions of the unprecedented cancer research consortium when PICI launched in 2016, through an initial $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker.
The continued collaboration will support laboratory studies and clinical trials that leverage the science of cancer immunology, as well as training of early-career scientists, at the ACC, an international leader in basic, translational, and clinical cancer immunotherapy research.
Read more here: